Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Castaneda Puglianini on Next Steps With CAR T-Cell Therapy in Multiple Myeloma

October 13th 2021

Omar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

Dr. Blue on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

October 13th 2021

Brandon Blue, MD, discusses treatment considerations for patients with relapsed/refractory multiple myeloma.

Dr. Brayer on Alternatives to CAR T-Cell Therapy in Multiple Myeloma

October 12th 2021

Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma. 

Dr. Hansen on the Promise of ALLO-715 in Relapsed/Refractory Multiple Myeloma

October 12th 2021

Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.

Dr. Ghobrial on the Key Objectives of the PROMISE Study in Multiple Myeloma

October 11th 2021

Irene Ghobrial, MD, discusses the key objectives of the PROMISE study in multiple myeloma.

Dr. Baljevic on the Current Limitations of CAR T-Cell Therapy in Multiple Myeloma

October 8th 2021

Muhamed Baljevic, MD, discusses the current limitations of CAR T-cell therapy in multiple myeloma.

Dr. Popat on Mitigating Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

October 8th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses mitigating belantamab mafodotin-blmf–related keratopathy in relapsed/refractory multiple myeloma.

Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma

October 8th 2021

The FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance.

Dr. Sborov on Supportive Care Approaches to Selinexor-Associated Toxicities in Multiple Myeloma

October 7th 2021

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Dr. Hansen on the PFS Benefit With Ide-Cel in Relapsed/Refractory MM

October 7th 2021

Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.

Dr. Anderson on the Methods Utilized in the KarMMa Trial in Multiple Myeloma

October 6th 2021

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Dr. Castaneda Puglianini on Outcomes With Cilta-Cel in Relapsed/Refractory Myeloma

October 6th 2021

Omar Castaneda Puglianini, MD, discusses results from the phase 1b/2 CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma. 

Dr. Baz on the Role of Alkylating Agents in Relapsed/Refractory Multiple Myeloma

October 5th 2021

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.

Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

October 1st 2021

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

Dr. Dholaria on the Rationale for the MagnetisMM-1 Trial in Multiple Myeloma

September 30th 2021

Bhagirathbhai Dholaria, MBBS, discusses the rationale for the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Dr. Sborov on Managing Bispecific Antibody–Related Adverse Effects in Multiple Myeloma

September 29th 2021

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Dr. Baz on the Utility of Venetoclax in Heavily Pretreated Multiple Myeloma

September 29th 2021

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

Dr. Manasanch on Eligibility for Autologous Transplant in Multiple Myeloma

September 28th 2021

Elisabet E. Manasanch, MD, discusses eligibility for autologous stem cell transplant in patients with multiple myeloma.

​Dr. Shah on the Potential of Vaccine-Based Therapy in Multiple Myeloma

September 28th 2021

Nina Shah, MD, discusses the potential of vaccine-based therapies in multiple myeloma.

Dr. Popat on Weighing Belantamab Mafodotin–Related Toxicities in Multiple Myeloma

September 27th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses the toxicities associated with belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

NEXT PAGE
PREVIOUS PAGE